These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Reck M Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737 [TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for the treatment of non-small cell lung cancer. Muller M; Schouten RD; De Gooijer CJ; Baas P Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376 [TBL] [Abstract][Full Text] [Related]
5. [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma]. Zarza V; Couraud S; Bosc C; Toffart AC; Moro-Sibilot D; Souquet PJ Rev Mal Respir; 2014 Sep; 31(7):601-7. PubMed ID: 25239581 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Shafique M; Tanvetyanon T Expert Opin Biol Ther; 2019 Mar; 19(3):225-232. PubMed ID: 30657338 [TBL] [Abstract][Full Text] [Related]
7. [Pembrolizumab in adjuvant therapy in non-small cell lung cancers]. Lefèvre A; Tissot C Bull Cancer; 2024 Apr; 111(4):334-336. PubMed ID: 38471995 [No Abstract] [Full Text] [Related]
8. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Dang TO; Ogunniyi A; Barbee MS; Drilon A Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948 [TBL] [Abstract][Full Text] [Related]
9. Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient. Saito S; Toyokawa G; Momosaki S; Kozuma Y; Shoji F; Yamazaki K; Takeo S Thorac Cancer; 2021 Aug; 12(15):2217-2220. PubMed ID: 34151529 [TBL] [Abstract][Full Text] [Related]
10. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021 [TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer. Blanchard A; Bouchard N Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826 [TBL] [Abstract][Full Text] [Related]
12. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420 [TBL] [Abstract][Full Text] [Related]
13. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer. Uprety D Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572 [No Abstract] [Full Text] [Related]
14. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer. Casas F; Viñolas N; Ferrer F; Agustí C; Sanchez M; Maria Gimferrer J; Lomeña F; Campayo M; Jeremic B J Thorac Oncol; 2011 Jan; 6(1):79-85. PubMed ID: 21150466 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ; J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112 [TBL] [Abstract][Full Text] [Related]
17. [Management of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response]. Storme S; Debieuvre D; Souquet PJ; Toffart AC; Couraud S Rev Mal Respir; 2022 Sep; 39(7):578-586. PubMed ID: 35909007 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966 [TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Ohguri T; Imada H; Narisada H; Yahara K; Morioka T; Nakano K; Miyaguni Y; Korogi Y Int J Hyperthermia; 2009 Mar; 25(2):160-7. PubMed ID: 19337916 [TBL] [Abstract][Full Text] [Related]
20. [Treatment and prognosis of advanced stage non-small-cell lung cancer]. Chermiti Ben Abdallah F; Ben Ali G; Sadok Boudaya M; Mlika M; Chtourou A; Taktak S; Ben Kheder A Rev Mal Respir; 2014 Mar; 31(3):214-20. PubMed ID: 24680112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]